| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| 500mg |
|
||
| 1g |
|
||
| 2g |
|
||
| Other Sizes |
|
Purity: ≥98%
Desloratadine (formerly SCH34117, NSC 675447; SCH-34117, NSC-675447; Clarinex; Neoclarityn; Descarboethoxyloratadine; Aerius) is the active metabolite of loratadine which is an anti-histamine drug of the tricyclic class used to treat allergies. Desloratadine is a potent antagonist of the human histamine H1 receptor with an IC50 of 51 nM.
| Targets |
Histamine H1 receptor ( IC50 = 51 nM )
|
||
|---|---|---|---|
| ln Vitro |
|
||
| ln Vivo |
|
||
| Animal Protocol |
|
||
| References |
| Molecular Formula |
C19H19CLN2
|
|
|---|---|---|
| Molecular Weight |
310.82
|
|
| Exact Mass |
310.12
|
|
| Elemental Analysis |
C, 73.42; H, 6.16; Cl, 11.41; N, 9.01
|
|
| CAS # |
100643-71-8
|
|
| Related CAS # |
Desloratadine-d4; 381727-29-3; Desloratadine-d9; 1795024-82-6; Desloratadine-3,3,5,5-d4; 2713301-38-1; Desloratadine-d5; 1020719-34-9
|
|
| Appearance |
Solid powder
|
|
| SMILES |
C1CC2=C(C=CC(=C2)Cl)C(=C3CCNCC3)C4=C1C=CC=N4
|
|
| InChi Key |
JAUOIFJMECXRGI-UHFFFAOYSA-N
|
|
| InChi Code |
InChI=1S/C19H19ClN2/c20-16-5-6-17-15(12-16)4-3-14-2-1-9-22-19(14)18(17)13-7-10-21-11-8-13/h1-2,5-6,9,12,21H,3-4,7-8,10-11H2
|
|
| Chemical Name |
13-chloro-2-piperidin-4-ylidene-4-azatricyclo[9.4.0.03,8]pentadeca-1(11),3(8),4,6,12,14-hexaene
|
|
| Synonyms |
|
|
| HS Tariff Code |
2934.99.9001
|
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
|
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
|
|||
|---|---|---|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (8.04 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (8.04 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (8.04 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. Solubility in Formulation 4: 30% Propylene glycol , 5% Tween 80 , 65% D5W: 30 mg/mL |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.2173 mL | 16.0865 mL | 32.1730 mL | |
| 5 mM | 0.6435 mL | 3.2173 mL | 6.4346 mL | |
| 10 mM | 0.3217 mL | 1.6086 mL | 3.2173 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
| NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
| NCT05214911 | Not yet recruiting | Drug: Desloratadine , Prednisolone Drug: Desloratadine |
Allergic Rhinitis | Eurofarma Laboratorios S.A. | March 30, 2024 | Phase 3 |
| NCT05446480 | Recruiting | Drug: Desloratadine Drug: Placebo |
Heat Stress, Exertional Inflammatory Response |
University of Victoria | July 2022 | Not Applicable |
| NCT01314352 | Completed | Drug: Desloratadine | Fed | Dr. Reddy's Laboratories Limited | December 2005 | Phase 1 |
| NCT01314339 | Completed | Drug: Desloratadine | Fasting | Dr. Reddy's Laboratories Limited | December 2005 | Phase 1 |
| NCT01506037 | Completed | Drug: Desloratadine | Healthy | Dr. Reddy's Laboratories Limited | January 2006 | Phase 1 |
 Identification of CRx-153, i.e., the combination of desloratadine and nortriptyline activity.Cell Immunol. 2011; 270(2): 237–250. |
|---|
 |
 |
 |
|---|
 |
 |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA